Prognostic Significance of Immunohistochemically Localized Biomarkers in Stage II and Stage III Breast Cancer: A Multivariate Analysis
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: The aim was to investigate the expression of a panel of biomarkers such as prolactin (PRL), p53, Bcl-2, c-erb B2, Ki-67, CD44, and factor VIII-related antigen (FVIII-RA) in primary tumors of stage II and stage III breast cancer and its correlation with disease prognostication.
Methods: The streptavidin-biotin peroxidase complex technique was used for the detection of these antigens. Cytoplasmic staining pattern was observed for PRL, Bcl-2, and Ki-67. Staining pattern for p53 was nuclear. Membranous and/or cytoplasmic staining was noted for c-erb B2 and CD44. Microvessel staining was noted for FVIII-RA.
Results: Of the 93 primary breast tumors analyzed, positivity for PRL was noted in 82%, for p53 in 56%, for Bcl-2 in 73%, for c-erb B2 in 68%, and for Ki-67 and CD44 in 78% each. The microvessel count (MVC) for FVIII-RA ranged from 0.0 to 29.0, with a median of 6.0, which was used as a cutoff. MVC $ 6.0 was noted in 51% of breast tumors. With increasing tumor size, the higher frequency of positivity of MVC $ 6.0 (P 5 .0001), CD44 (P 5 .001), PRL (P 5 .002), and c-erb B2 (P 5 .008), and higher frequency of Bcl-2 negativity (P 5 .033), was noted. In stage III patients, a higher positivity of the following biomarkers was noted, compared with stage II patients: MVC $ 6.0 (P 5 .0004), PRL (P 5 .0002), c-erb B2 (P 5 .001), and CD44 (P 5 .005). Further, Bcl-2 positivity was significantly lower in patients with stage III disease compared with those with stage II disease (P 5 .024). In patients with nodal involvement, the frequency of c-erb B2 (P 5 .006), MVC $ 6.0 (P 5 .011), and PRL (P 5 .032) was higher than in those without nodal involvement. Moreover, in these patients, with the increase in the number of involved lymph nodes, there was a significant increase in frequency of CD441 (P 5 .0004) and PRL1 (P 5 .013) tumors. Abnormal expression of one biomarker was seen in 7% of tumors, of two biomarkers in 4%, of three in 15%, of four in 19%, of five in 28%, of six in 20%, and of all seven biomarkers in 7% of tumors. The frequency of an increasing number of biomarkers coexpressed was higher in stage III patients compared with stage II patients (P 5 .00003). In the total number of patients (n 5 93), tumors with Bcl-2 negativity (P 5 .00001), MVC $ 6.0 (P 5 .001), PRL positivity (P 5 .02), and CD44 positivity (P 5 .034) had a significantly poorer overall survival (OS) compared with their respective counterparts. In stage II patients (n 5 40), only p53 expression was significantly associated with reduced relapse-free survival (P 5 .009) and OS (P 5 .040). In multivariate analysis, p53 expression was an independent prognostic factor that influenced relapse-free survival (P 5 .034) of stage II breast cancer patients. However, it failed to attain statistical significance for OS. In stage III patients (n 5 53), tumors with Bcl-2 negativity (P 5 .0005) and MVC $ 6.0 (P 5 .039) had a significantly poorer OS compared with their respective counterparts. In multivariate analysis of stage III patients, Bcl-2 was the only independent prognostic factor (P 5 .001) for predicting OS. There was a significant association between coexpression of the biomarkers and OS (P 5 .001). The OS rates decreased with the increase in number of abnormally expressed biomarkers.
Conclusions: p53 expression in primary tumors was an independent prognostic factor that influenced relapse-free survival in patients with stage II disease. In stage III patients, lack of Bcl-2 expression was independently associated with a poor prognosis and, thus, may be an indicator of aggressive phenotype.
- Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434–438.
- Gasparini G, Gullick WJ, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992;10:686–695.
- Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39–47.
- Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995; 60:54–60.
- Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615–619.
- Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6. CrossRef
- Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993;10:302–313.
- Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of breast cancer metastasis. Cell 1994;79: 185–188.
- Weikel W, Beck T, Mitze M, Knapstein PG. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 1991;18: 149–154.
- Bhatavdekar JM, Giri DD, Shah NG, et al. Prolactin in advanced breast cancer: an Indian experience. Breast Dis 1990;3:199–204.
- Bhatavdekar JM, Shah NG, Balar DB, et al. Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer 1990;65:2028–2032.
- Patel DD, Bhatavdekar JM, Chikhlikar PR, et al. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996;62:86–92.
- Bhatavdekar JM, Patel DD, Shah NG, et al. Role of prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000. (In press).
- UICC TNM classification of malignant tumors. Breast (ICD-O THE-174). In: Seller AH, ed. UICC Technical Report Series,vol. 51 . 1st edn. Geneva, Switzerland, 1980, p 7.
- Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359–377.
- Bhatavdekar JM, Patel DD, Chikhlikar PR, et al. Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol 1998;5:495–501.
- Norusis MJ. SPSS (SPSS for Windows: Base System User’s Guide, Release 6.0). Chicago: SPSS Inc., 1993.
- McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006–1015.
- Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein co-expression: value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995;221:706–720.
- Han S, Yun I-J, Noh D-Y, Choe K-J, Song S-Y, Chi JG. Abnormal expression of four novel molecular marker represents a highly aggressive phenotype in breast cancer: immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 1997;65:22–27.
- Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991;164:75–81.
- Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454–466.
- Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred DC. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 1993;27:95–102.
- Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Downregulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095–2097.
- Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia: W.B. Saunders, 1995:206–232.
- Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956–2963.
- Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer 1995;75:1320–1326.
- Wintzer H-O, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421–428.
- Locker AP, Birrell K, Bell JA, et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 1992;18:224–229.
- Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994;57:822–829.
- Prognostic Significance of Immunohistochemically Localized Biomarkers in Stage II and Stage III Breast Cancer: A Multivariate Analysis
Annals of Surgical Oncology
Volume 7, Issue 4 , pp 305-311
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Stage II and stage III breast cancer
- Prognostic factor
- Industry Sectors
- Author Affiliations
- 1. Department of Cancer Biology, Gujarat Cancer and Research Institute, NCH Compound, Asarwa, Ahmedabad, 380 016, India
- 2. Department of Speciality Clinics of Surgery, Gujarat Cancer and Research Institute, NCH Compound, Asarwa, Ahmedabad, 380 016, India
- 3. Division of Molecular Endocrinology, Gujarat Cancer and Research Institute, NCH Compound, Asarwa, Ahmedabad, 380 016, India
- 4. Department of Cancer Biology, Gujarat Cancer and Research Institute, NCH Compound, Asarwa, Ahmedabad, 380 016, India